Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Siglec15 in blood system diseases: from bench to bedside

4 Dec 2024

Abstract excerpt

Inhibiting the PD-1/PD-L1 pathway using immunomodulators has demonstrated promising outcomes in clinics. Immunomodulators can effectively target immune checkpoints with a strong preference for the tumor microenvironment (TME). Besides, immunomodulators specifically target the recently discovered inhibitory immune checkpoint, sialic acid-binding immunoglobulin-like lectin (Siglec-15). Distinctive in its molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Galectins and Cancer Biology
Share to Glycosylation and Glycoproteins Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39697338
DOI: 10.3389/fimmu.2024.1490505

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Siglec15 in blood system diseases: from bench to bedsidePMID 39697338Read ↗

Siglec-15 as an Emerging Target for Next-generation Cancer ImmunotherapySemantic proximity Read ↗

Molecular structure, expression, and the emerging role of Siglec‐15 in skeletal biology and cancerSemantic proximity Read ↗

Integrative Analysis of Siglec-15 mRNA in Human Cancers Based on Data MiningSemantic proximity Read ↗

Identification and characterization of three Siglec15-related immune and prognostic subtypes of breast-invasive cancer.Semantic proximity Read ↗

Siglec-15 is a glyco-immune checkpoint in prostate cancer regulating immune evasion and metastasisSemantic proximity Read ↗

Unveiling the molecular features, relevant immune and clinical characteristics of SIGLEC15 in thyroid cancerSemantic proximity Read ↗

Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy.Semantic proximity Read ↗

Comprehensive Analysis of SIGLEC-15 and PD-L1 Expression Identifies Distinct Prognostic Profiles in Gastric CancerSemantic proximity Read ↗

Integrative Analysis of the Expression of SIGLEC Family Members in Lung Adenocarcinoma via Data MiningSemantic proximity Read ↗

CD151—A Striking Marker for Cancer TherapySemantic proximity Read ↗

Tumor Derived SIGLEC Family Genes May Play Roles in Tumor Genesis, Progression, and Immune Microenvironment RegulationSemantic proximity Read ↗

Impact of Overexpression of Immune Suppressor Siglec-15 on The Prognosis of Clear Renal Cell Carcinoma and Fibrosis LevelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.